Detalhe da pesquisa
1.
Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aß42/40 ratio to identify presence of brain amyloid.
Alzheimers Dement
; 20(5): 3179-3192, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38491912
2.
Associations of sleep duration and daytime sleepiness with plasma amyloid beta and cognitive performance in cognitively unimpaired, middle-aged and older African Americans.
Sleep
; 47(1)2024 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38011629
3.
Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment.
JAMA Netw Open
; 5(4): e228392, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35446396
4.
A blood-based diagnostic test incorporating plasma Aß42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis.
Mol Neurodegener
; 16(1): 30, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33933117
5.
The PrecivityAD™ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis.
Clin Chim Acta
; 519: 267-275, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34015303